Cellyan Biotechnology Co., Ltd filed a Form 6-K on November 16, 2026, disclosing that it received a letter from Nasdaq on November 13, 2026, confirming the company had regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.
Key Highlights
- Compliance letter received: Nasdaq notified Cellyan Biotechnology on November 13, 2026, that the minimum bid price matter is now closed.
- 14 consecutive business days: The company's Class A ordinary shares maintained a closing bid price at or above $1.00 per share from October 26 through November 12, 2026.
- Rule satisfied: The company regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing.
- Exchange and listing: The company's Class A ordinary shares are listed on the Nasdaq Capital Market (NASDAQ:HKPD).
- Jurisdiction: Cellyan Biotechnology Co., Ltd is incorporated in the Cayman Islands, with its principal executive office in Hong Kong.
Cellyan Biotechnology Closes Nasdaq Bid Price Matter After 14-Day Compliance Window
According to the Form 6-K filed with the U.S. Securities and Exchange Commission on November 16, 2026, Cellyan Biotechnology Co., Ltd received a letter from the Listing Qualifications Department of the Nasdaq Stock Market on November 13, 2026. The letter stated that the company's Class A ordinary shares had maintained a closing bid price at or above $1.00 per share for 14 consecutive business days, covering the period from October 26 through November 12, 2026.
The filing disclosed that, as a result of this sustained bid price, Cellyan Biotechnology had regained compliance with Nasdaq Listing Rule 5550(a)(2), which sets the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The filing further noted that "the matter is now closed," quoting directly from the Nasdaq letter. The company files annual reports under Form 20-F, as indicated on the cover of the filing.
The report was signed on November 16, 2026, by Chenyu Liang, identified in the filing as Director and Chief Executive Officer of Cellyan Biotechnology Co., Ltd. A press release was attached as Exhibit 99.1 to the filing.
What Was Disclosed
Cellyan Biotechnology filed a Form 6-K reporting that Nasdaq confirmed, on November 13, 2026, that the company had regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and that the matter is closed.




Please wait processing your request...